These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 23370134)

  • 21. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group.
    Lis Y; Roberts MH; Kamble S; J Guo J; Raisch DW
    Value Health; 2012 Dec; 15(8):1108-18. PubMed ID: 23244814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Summaries of Safety Labeling Changes Approved By FDA--Boxed Warnings Highlights July--September 2015.
    Am J Health Syst Pharm; 2015 Dec; 72(23):2008. PubMed ID: 26581924
    [No Abstract]   [Full Text] [Related]  

  • 23. Stakeholders say FDA must change REMS program.
    Reinke T
    Manag Care; 2011 Mar; 20(3):8-9. PubMed ID: 21485624
    [No Abstract]   [Full Text] [Related]  

  • 24. FDA urged to reduce REMS program burdens.
    Traynor K
    Am J Health Syst Pharm; 2015 Nov; 72(22):1916-21. PubMed ID: 26541942
    [No Abstract]   [Full Text] [Related]  

  • 25. Specialty pharmacies and other restricted drug distribution systems: financial and safety considerations for patients and health-system pharmacists.
    Kirschenbaum BE
    Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S13-20. PubMed ID: 19966075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Opioid risk management: understanding FDA mandated risk evaluation and mitigation strategies (REMS).
    Sloan PA
    J Opioid Manag; 2009; 5(3):131-3. PubMed ID: 19662921
    [No Abstract]   [Full Text] [Related]  

  • 27. Risk evaluation and mitigation strategies (REMS): educating the prescriber.
    Nicholson SC; Peterson J; Yektashenas B
    Drug Saf; 2012 Feb; 35(2):91-104. PubMed ID: 22171604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stakeholders urge overhaul of REMS programs: Standardization, better access, less paperwork sought.
    Traynor K
    Am J Health Syst Pharm; 2010 Sep; 67(17):1397-8. PubMed ID: 20720233
    [No Abstract]   [Full Text] [Related]  

  • 29. Understanding risk evaluation and mitigation strategies in organ transplantation.
    Gabardi S
    Pharmacotherapy; 2011 Jul; 31(7):714-22. PubMed ID: 21923459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NCCN Oncology Risk Evaluation and Mitigation Strategies White Paper: Recommendations for Stakeholders.
    Johnson PE; Dahlman G; Eng K; Garg R; Gottlieb S; Hoffman JM; Howell P; Jahanzeb M; Johnson S; Mackler E; Rubino M; Sarokhan B; Marc Stewart F; Tyler T; Vose JM; Weinstein S; Li EC; Demartino J;
    J Natl Compr Canc Netw; 2010 Sep; 8 Suppl 7():S7-S27. PubMed ID: 20947724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. White paper on designing a risk evaluation and mitigation strategies (REMS) system to optimize the balance of patient access, medication safety, and impact on the health care system.
    American Pharmacists Association
    J Am Pharm Assoc (2003); 2009; 49(6):729-43. PubMed ID: 19926553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk evaluation and mitigation strategies: assessment of a medical center's policies and procedures.
    Childs L; Alexander E; Duong MT
    Am J Health Syst Pharm; 2012 May; 69(10):885-9. PubMed ID: 22555085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Using technology to enhance measurement of drug-use safety.
    Schneider PJ
    Am J Health Syst Pharm; 2002 Dec; 59(23):2330-2. PubMed ID: 12489374
    [No Abstract]   [Full Text] [Related]  

  • 34. Risk Evaluation and Mitigation Strategies (REMSs): Are They Improving Drug Safety? A Critical Review of REMSs Requiring Elements to Assure Safe Use (ETASU).
    Boudes PF
    Drugs R D; 2017 Jun; 17(2):245-254. PubMed ID: 28160230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Communication of medical product risk: how effective is effective enough?
    Goldman SA
    Drug Saf; 2004; 27(8):519-34. PubMed ID: 15154825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Shared risk evaluation mitigation strategy for all immediate-release transmucosal fentanyl dosage forms.
    Food And Drug Administration, Public Health Service, U.S. Department Of Health And Human Services
    J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):123-6. PubMed ID: 22764848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improving the Food and Drug Administration's mandate to ensure postmarketing drug safety.
    Qato DM; Alexander GC
    JAMA; 2011 Oct; 306(14):1595-6. PubMed ID: 21990303
    [No Abstract]   [Full Text] [Related]  

  • 38. Implications of Risk Evaluation and Mitigation Strategy (REMS) programs for managed care pharmacy.
    ; Gandhi G; Chon A; Johnson N; Kidder PA; Lee P; Leung K; Ma I; Ness S; Sampsel E; Schlaifer M; Seifert R; Sternaman DB
    J Manag Care Pharm; 2012 Apr; 18(3):268-75. PubMed ID: 22468736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Documenting an adverse drug reaction.
    Smith LS
    Nursing; 2005 Oct; 35(10):22. PubMed ID: 16205246
    [No Abstract]   [Full Text] [Related]  

  • 40. [Risk management--adverse effects of pharmaceutical products. Interpretation of the drug package inserts].
    Mochizuki M
    Nihon Jibiinkoka Gakkai Kaiho; 2005 Aug; 108(8):814-7. PubMed ID: 16267911
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.